<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838237/" ref="ordinalpos=584&amp;ncbi_uid=2236152&amp;link_uid=PMC2838237" image-link="/pmc/articles/PMC2838237/figure/F1/" class="imagepopup">Fig. 1.  From: THERAPEUTIC TARGETING OF "DARPP-32": A KEY <span class="highlight" style="background-color:">SIGNALING</span> MOLECULE IN THE DOPIMINERGIC <span class="highlight" style="background-color:">PATHWAY</span> FOR THE TREATMENT OF OPIATE ADDICTION. </a></div><br /><div class="p4l_captionBody">Schematic of a signaling cascade activated by opiates. Opiates via the Î¼-opioid receptor activates the dopiminergic pathway leading to the increased DARPP-32 phosphorylation at Thr34 and increased PP-1 inhibition which modulates ERK activation and consequently the expression of the downstream transcriptional molecule CREB.</div></div>